



>>**Abetimus**, INN

LJP 394

GQO20-R

[167362-48-3]

Classification:XA4800

$C_{1632}H_{2100}N_{610}O_{970}P_{156}S_4$ M 50742.224. 50717.170342. C 38.63%; H 4.17%; N 16.84%; O 30.58%; P 9.52%; S 0.25%

Double-stranded oligonucleotide-platform conjugate. Inhibits binding of DNA to anti-double-stranded oligonucleotide antibodies. Therapeutic candidate for the treatment of lupus nephritis. Immunosuppressant

>>*Na salt*: **Abetimus sodium**, USAN . HOH97-H [169147-32-4]

Jones, D.S. *et al.*, *J. Med. Chem.*, 1995, **38**, 2138-2144, (*synth, props, activity*)

U.S. Pat., 1996, *La Jolla*, 5 552 391; *CA*, **125**, 219609p, (*synth, pharmacol*)

Weisman, M.H. *et al.*, *J. Rheumatol.*, 1997, **24**, 314-318, (*use*)

Illei, G.G. *et al.*, *Lupus*, 1998, **7**, 644-648, (*rev*)